植田 佑樹 (ウエダ ユウキ)

北海道大学病院 小児・周産・女性科助教

2003年 北海道大学医学部卒
2013年 北海道大学大学院医学研究科博士課程修了
北海道大学医学部小児科所属
小児科専門医・指導医
てんかん専門医 小児神経専門医

研究者基本情報

■ URL
researchmap URLホームページURL■ ID 各種
J-Global ID■ 研究キーワード・分野
研究分野
  • ライフサイエンス, 病態神経科学
■ 担当教育組織

経歴

■ 経歴
経歴
  • 2024年05月 - 現在
    北海道大学病院, 小児科, 助教

研究活動情報

■ 論文
  • A Pediatric Case of Homocystinuria Due to MTHFR Deficiency with Early Clinical Features Resembling Leigh Encephalopathy
    Tatsunori Itabashi; Jiro Abe; Midori Nakajima; Yuki Ueda; Kiyoshi Egawa; Masayoshi Nagao; Atsuhito Takeda
    Children, 2026年09月30日
    研究論文(学術雑誌)
  • Beta event-related synchronization after muscle contraction is modulated by voluntary movement patterns: An EEG and MEG study
    Rin Kosuge; Hidekazu Saito; Yuya Matsuda; Mayu Akaiwa; Ryo Kurokawa; Yasushi Sugawara; Eriko Shibata; Takeshi Sasaki; Jun Shinozaki; Yuki Ueda; Kazuhiro Sugawara
    NeuroImage, 2026年09月
    研究論文(学術雑誌)
  • Region‐dependent differences in tonic inhibition underlie epileptic features in Angelman syndrome model mice
    Miho Watanabe; Takeru Goto; Ryoko Miyoshi; Sachiko Nakakubo; Yasuyoshi Hiramatsu; Midori Nakajima; Yuki Ueda; Hideaki Shiraishi; Atsushi Manabe; Prithu Mondal; Dishary Sharmin; Michael Ming Poe; James M. Cook; Kiyoshi Egawa
    Epilepsia, 2026年08月
    研究論文(学術雑誌)
  • Clinical practices in prehospital rescue medication use for pediatric status epilepticus in Japan: a nationwide questionnaire survey.
    Masahiro Nishiyama; Yuki Ueda; Ryuki Matsuura; Tadashi Shiohama; Mitsuo Motobayashi; Masataka Fukuoka; Shizuka Oikawa; Sotaro Kanai; Michiko Torio; Ichiro Kuki; Hiroaki Nagase; Tomoyuki Akiyama; Kenjiro Kikuchi; Yoshihiro Maegaki
    Brain & development, 48, 4, 104573, 104573, 2026年07月11日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Status epilepticus (SE) is a neurological emergency requiring rapid treatment. While prehospital management is critical, practices regarding rescue medication use and caregiver guidance, including emergency service activation, remain unclear. METHODS: We conducted a nationwide, web-based survey of pediatric neurologists between January and March 2025. One representative from each institution reported on rescue medication prescribing and caregiver instructions for prehospital seizure management. The survey assessed indications for buccal midazolam, scenario-based recommendations, and post-administration guidance. RESULTS: Of 136 responses, 134 respondents who were aware of buccal midazolam were included; 118 had prescribing experience. A history of prolonged convulsive seizures, particularly ≥30 min (95.5% high-priority), was consistently identified as a high-priority indication. Seizures lasting 5-30 min were also considered appropriate (57.5% high-priority, 38.1% low-priority), with greater variability. In contrast, frequent seizures alone were often regarded as appropriate (44.8% low-priority) but rarely high-priority (16.4%). Diagnostic categories such as epilepsy or febrile seizures themselves were not regarded as appropriate indications. Environmental factors, including distance from medical facilities, were also relevant. Similar patterns were observed in scenario-based recommendations, with consistent findings across epilepsy and febrile seizure scenarios. Caregiver instructions varied widely, particularly regarding emergency service activation. In-hospital management was generally unchanged regardless of prehospital rescue medication use. CONCLUSIONS: Prehospital rescue medication prescribing is primarily guided by seizure duration rather than diagnostic categories. Variability in caregiver instructions highlights the need for clearer guidance to optimize prehospital seizure management.
  • Combined Intracerebroventricular Enzyme Replacement and Cord Blood Transplantation in Patients with Mucopolysaccharidosis Type II Diagnosed Through Newborn Screening
    Yuki Ueda; Shinsuke Hirabayashi; Masayuki Miura; Satoshi Yamada; Sachiko Nakakubo; Midori Nakajima; Takeru Goto; Jutaro Abe; Yukayo Terashita; Atsushi Manabe; Torayuki Okuyama; Kiyoshi Egawa
    International Journal of Neonatal Screening, 2026年06月
    研究論文(学術雑誌)
  • Thalamic Volume Asymmetry as a Potential Predictor of Vagus Nerve Stimulation Outcomes in Refractory Epilepsy.
    Masaki Ujihara; Masahito Kawabori; Midori Nakajima; Yuki Ueda; Toru Horinouchi; Kiyoshi Egawa; Takahiro A Kato; Miki Fujimura
    Neurologia medico-chirurgica, 2026年05月27日, [国内誌]
    英語, 研究論文(学術雑誌), Vagus nerve stimulation is an established treatment for refractory epilepsy, but predictors of treatment response remain unclear. Given that left-sided vagus nerve stimulation preferentially modulates the left thalamus and that epileptic networks induce thalamic structural damage, we investigated whether preoperative thalamic volume asymmetry predicts vagus nerve stimulation outcomes. This retrospective study included 17 patients with refractory epilepsy who underwent vagus nerve stimulation implantation. Patients were classified as responders (≥50% seizure reduction at 24 months, n = 9) or non-responders (n = 8). Thalamic volumes were manually segmented on preoperative T2-weighted magnetic resonance imaging by 2 blinded raters, and we used the rater-averaged values to calculate the left/right volume ratio and asymmetry index. The mean thalamic volume ratio (left/right) was significantly higher in responders than non-responders (1.00 [95% confidence interval 0.97-1.03] vs 0.96 [95% confidence interval 0.92-0.99], p = 0.027), and the asymmetry index also differed between groups (0.00 [95% confidence interval -0.015 to 0.017] vs -0.023 [95% confidence interval -0.040 to -0.006], p = 0.027). Inter-rater reliability was acceptable for absolute volumes but was lower for ratio-based asymmetry indices, suggesting that these derived metrics may be more suitable for group-level comparisons than for single-patient prediction. Epileptogenic laterality determined by electroencephalography did not predict thalamic asymmetry. Relative left thalamic volume reduction was associated with poor vagus nerve stimulation treatment response. Assessment of preoperative thalamic asymmetry on routine structural magnetic resonance imaging may represent a candidate biomarker for predicting vagus nerve stimulation efficacy, pending validation in larger cohorts.
  • Management of pediatric status epilepticus after hospital arrival in Japan: A nationwide questionnaire survey.
    Nishiyama M; Ueda Y; Matsuura R; Shiohama T; Motobayashi M; Fukuoka M; Oikawa S; Kanai S; Torio M; Kuki I; Nagase H; Akiyama T; Kikuchi K; Maegaki Y
    Brain & development, 2026年03月17日
    研究論文(学術雑誌),

    Background

    Status epilepticus (SE) is a neurological emergency requiring rapid, stepwise treatment. In Japan, the Guidelines for the Treatment of Pediatric Status Epilepticus 2023 (GL2023) were published; however, real-world practice following their publication remains unclear.

    Methods

    We conducted a nationwide, cross-sectional web-based survey of pediatric neurologists between January and March 2025. One representative from each institution reported institutional practices for the in-hospital management of pediatric SE. Institutions were stratified by annual SE case volume (≥20 vs. ≤19 cases). General management strategies, antiseizure medication selection, electroencephalography (EEG) utilization, and approaches to refractory and super-refractory SE (RSE and SRSE) were analyzed.

    Results

    A total of 136 institutions responded. Most institutions reported referring to GL2023 and initiating first-line treatment within 10 min of hospital arrival. Midazolam was the most commonly used first-line drug, with widespread use of non-intravenous routes. Phenytoin or fosphenytoin remained the most commonly selected second-line drug, followed by phenobarbital. For RSE, anesthetic coma therapy with midazolam and barbiturates was used at comparable frequencies. Overall, antiseizure medication selection did not differ by institutional case volume. In contrast, institutions managing ≥20 cases annually more frequently reported having institution-specific protocols, utilizing EEG in the emergency department, administering repeat doses of benzodiazepines, and having experience with advanced therapies for SRSE.

    Conclusions

    Pediatric SE management in Japan emphasizes rapid treatment and flexible administration routes. Institutional experience is associated with differences in EEG utilization, protocol development, and SRSE management. Further improvement will require continued evidence generation, timely treatment implementation, and reduction of institutional disparities.
  • 神経救急の進歩 小児てんかん重積状態・けいれん重積状態の治療法に関するアンケート調査 病院前治療の実態
    西山 将広; 植田 佑樹; 塩濱 直; 松浦 隆樹; 本林 光雄; 福岡 正隆; 老川 静香; 金井 創太郎; 鳥尾 倫子; 菊池 健二郎; 九鬼 一郎; 永瀬 裕朗; 秋山 倫之; 前垣 義弘
    てんかん研究, 43, 2, 330, 330, (一社)日本てんかん学会, 2025年09月
    日本語
  • 小児てんかん重積状態・けいれん重積状態の治療法に関するアンケート調査 病院到着後の治療実態
    西山 将広; 植田 佑樹; 塩濱 直; 松浦 隆樹; 本林 光雄; 福岡 正隆; 老川 静香; 金井 創太郎; 鳥尾 倫子; 菊池 健二郎; 九鬼 一郎; 永瀬 裕朗; 秋山 倫之; 前垣 義弘
    てんかん研究, 43, 2, 496, 496, (一社)日本てんかん学会, 2025年09月
    日本語
  • 突発性発疹に伴う脱力で発症したATP1A3遺伝子異常症、Relapsing Encephalopathy with Cerebellar Ataxia(RECA)の一例
    中久保 佐千子; 山田 聡; 平松 泰好; 後藤 健; 中島 翠; 植田 佑樹; 江川 潔; 白石 秀明
    日本遺伝カウンセリング学会誌, 46, 2, 171, 171, (一社)日本遺伝カウンセリング学会, 2025年07月
    日本語
  • 新規ナトリウムチャンネル拮抗薬をエトスクシミドに変更し著効した睡眠時棘徐波活性化を示すてんかん性脳症(EE-SWAS)の二例
    山田 聡; 江川 潔; 植田 佑樹; 中島 翠; 中久保 佐千子; 後藤 健; 平松 泰好; 福島 克之; 柳生 一自
    脳と発達, 57, Suppl., s240, s240, (一社)日本小児神経学会, 2025年06月
    日本語
  • Childhood autoimmune glial fibrillary acidic protein astrocytopathy with spinal cord FDG accumulation on 18F-FDG-PET imaging
    Tatsunori Itabashi; Yuki Ueda; Akio Kimura; Takayoshi Shimohata; Tomonobu Sato
    Brain and Development Case Reports, 2025年03月
    英語, 研究論文(学術雑誌)
  • Japanese guidelines for treatment of pediatric status epilepticus - 2023.
    Kikuchi K; Kuki I; Nishiyama M; Ueda Y; Matsuura R; Shiohama T; Nagase H; Akiyama T; Sugai K; Hayashi K; Murakami K; Yamamoto H; Fukuda T; Kashiwagi M; Maegaki Y
    Brain & development, 2024年12月02日
    研究論文(学術雑誌), The updated definition of status epilepticus (SE) by the International League Against Epilepsy in 2015 included two critical time points (t1: at which the seizure should be regarded as an "abnormally prolonged seizure"; and t2: beyond which the ongoing seizure activity can pose risk of long-term consequences) to aid in diagnosis and management and highlights the importance of early treatment of SE more clearly than ever before. Although Japan has witnessed an increasing number of pre-hospital drug treatment as well as first- and second-line treatments, clinical issues have emerged regarding which drugs are appropriate. To address these clinical concerns, a revised version of the "Japanese Guidelines for the Treatment of Pediatric Status Epilepticus 2023" (GL2023) was published. For pre-hospital treatment, buccal midazolam is recommended. For in-hospital treatment, if an intravenous route is unobtainable, buccal midazolam is also recommended. If an intravenous route can be obtained, intravenous benzodiazepines such as midazolam, lorazepam, and diazepam are recommended. However, the rates of seizure cessation were reported to be the same among the three drugs, but respiratory depression was less frequent with lorazepam than with diazepam. For established SE, phenytoin/fosphenytoin and phenobarbital can be used for pediatric SE, and levetiracetam can be used in only adults in Japan. Coma therapy is recommended for refractory SE, with no recommended treatment for super-refractory SE. GL2023 lacks adequate recommendations for the treatment of nonconvulsive status epilepticus (NCSE). Although electrographic seizure and electrographic SE may lead to brain damages, it remains unclear whether treatment of NCSE improves outcomes in children. We plan to address this issue in an upcoming edition of the guideline.
  • Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function.
    Yuki Ueda; Kiyoshi Egawa; Kentaro Kawamura; Noriki Ochi; Takeru Goto; Shuhei Kimura; Masashi Narugami; Sachiko Nakakubo; Midori Nakajima; Atsushi Manabe; Hideaki Shiraishi
    Brain & development, 2023年12月15日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Most long-term affected spinal muscular atrophy (SMA) type 1 patients have severe impairment of motor function and are dependent on mechanical ventilation with tracheostomy. The efficacy and safety of nusinersen in these patients have not been established. METHODS: We retrospectively evaluated the efficacy of intrathecal nusinersen treatment in patients with SMA type 1 who continued treatment for at least 12 months. There were three patients enrolled in our study (3, 4 and 16 years of age) who had severe impairment of gross motor function without head control or the ability to roll over. All three needed mechanical ventilation with tracheostomy and tube feeding. Motor function was assessed using the Children s Hospital of Philadelphia infant test of neuromuscular disorders (CHOP-INTEND) and the caregivers' evaluations. Concurrently, we examined nerve conduction longitudinally and compared compound motor action potential (CMAP) amplitudes. RESULTS: All patients continued nusinersen administration without significant adverse events for more than three years. While CHOP-INTEND scores did not remarkably increase, according to the caregivers, all three patients had improved finger or facial muscle movements that enabled them to make their intentions understood. Some CMAPs before treatment were not identified but became traces after nusinersen administration. CONCLUSIONS: The improvement in motor function that leads to smoother communication could be a basis for continuing nusinersen treatment. Currently available motor function scorings are not efficient for assessing therapeutic interventions in SMA patients with medical care complexity. Longitudinal nerve conduction studies could be an objective indicator.
  • Use of lacosamide for focal epilepsy in a child with kidney failure undergoing peritoneal dialysis.
    Yuki Ueda; Ayako Furugen; Masaki Kobayashi; Yasuyuki Sato; Yasuhiro Ueda; Asako Hayashi; Takeru Goto; Shuhei Kimura; Masashi Narugami; Sachiko Nakakubo; Midori Nakajima; Kiyoshi Egawa; Takayuki Okamoto; Atsushi Manabe; Hideaki Shiraishi
    Brain & development, 2023年10月30日, [国際誌]
    英語, BACKGROUND: Lacosamide (LCM) has become commonly used for focal onset seizures due to its high tolerability and low drug interactions. Unlike patients on hemodialysis (HD), pharmacokinetic data and dosing recommendations for patients undergoing peritoneal dialysis (PD) are scant. CASE REPORT: A 2-year-old girl with end-stage kidney disease undergoing PD suffered prolonged focal onset seizures. The patient had congenital anomalies of the kidney and urinary tract associated with branchio-oto-renal syndrome due to an EYA1 gene mutation. She also had neurological sequelae from post-resuscitation encephalopathy at the age of one month. Antiseizure medication with few drug interactions, less impact on the neurodevelopmental state and possibility of intravenous administration was preferred. LCM met those criteria and was carefully administered. Although the patient had recurrent prolonged seizures during the titration periods, LCM could be continued without any apparent side effects. The blood levels of LCM increased linearly to the optimal level. We confirmed excretion of LCM in the PD fluid. Kidney transplantation was done three months after and her seizures were well controlled. CONCLUSIONS: LCM might be a promising option for patients undergoing PD. Due to the lower removal efficacy in PD compared with in HD, close attention should be paid to possible drug excess.
  • Transcutaneous auricular vagus nerve stimulation therapy in patients with cognitively preserved structural focal epilepsy: A case series report.
    Hideaki Shiraishi; Kiyoshi Egawa; Kaoru Murakami; Midori Nakajima; Yuki Ueda; Sachiko Nakakubo; Masashi Narugami; Shuhei Kimura; Takeru Goto; Yasuyoshi Hiramatsu; Masaaki Murakami
    Brain & development, 2023年08月30日, [国際誌]
    英語, OBJECTIVE: Transcutaneous auricular vagus nerve stimulation (taVNS) was performed in two patients suffering structural focal epilepsy with preserved intellectual ability to show the feasibility of taVNS for specific patient groups. CASE PRESENTATIONS: Patient 1 was a 24-year-old woman with frontal lobe epilepsy who had weekly hyperkinetic seizures despite multiple anti-seizure medications. Patient 2 was a 27-year-old woman with parietal lobe epilepsy and focal cortical dysplasia in the vicinity of the lipoma in the corpus callosum. She experienced weekly focal-impaired awareness seizures even with anti-seizure medication. taVNS was applied to the left earlobe of both patients at 1.5 mA, 25 Hz, 250 μs pulse width, and 30 s stimulation with 30 s rest for 4 h per day. Over an 8-week baseline and 20 weeks of stimulation, the rate of reduction in seizure frequency was evaluated, along with quality-of-life using the Short-Form 36-Item Health survey. RESULTS: At baseline, we measured up to 11 and 12 focal seizures per week in Patient 1 and 2, respectively, with both patients achieving seizure freedom after 4 and 20 weeks taVNS, respectively. Patient 1 and 2 were observed for 18 and 14 months, respectively, including the clinical trial and follow-up observation period. Quality-of-life ratings increased in both patients, and no significant adverse events occurred during the study period. During the maintenance period after 20 weeks, seizures remained absent in Patient 1, and seizures remained reduced in Patient 2. CONCLUSION: Our results demonstrate that taVNS may be a promising tool for structural focal epilepsy with preserved cognitive function. A multicenter double-blind clinical trial is needed to confirm the role of taVNS as an anti-seizure tool.
  • Video-based detection of epileptic spasms in West syndrome using a deep neural network: A pilot case study.
    Katsuki Eguchi; Hiroaki Yaguchi; Sachiko Nakakubo; Midori Nakajima; Yuki Ueda; Kiyoshi Egawa; Hideaki Shiraishi; Ichiro Yabe
    Journal of the neurological sciences, 449, 120671, 120671, 2023年06月15日, [国際誌]
    英語
  • Efficacy of sirolimus for epileptic seizures in childhood associated with focal cortical dysplasia type II
    Hideaki Shiraishi; Tsuyoshi Teramoto; Saki Yokoshiki; Jun Tohyama; Yuki Ueda; Kiyoshi Egawa; Norihiro Sato; Atsushi Manabe; Mitsuhiro Kato
    BRAIN & DEVELOPMENT, 45, 6, 343, 347, 2023年06月
    英語, 研究論文(学術雑誌)
  • Therapeutic effects of KRM-II-81, positive allosteric modulator for α2/3 subunit containing GABAA receptors, in a mouse model of Dravet syndrome.
    Sachiko Nakakubo; Yasuyoshi Hiramatsu; Takeru Goto; Syuhei Kimura; Masashi Narugami; Midori Nakajima; Yuki Ueda; Hideaki Shiraishi; Atsushi Manabe; Dishary Sharmin; James M Cook; Kiyoshi Egawa
    Frontiers in pharmacology, 14, 1273633, 1273633, 2023年, [国際誌]
    英語, 研究論文(学術雑誌), Introduction: Dravet syndrome (DS) is an intractable epilepsy syndrome concomitant with neurodevelopmental disorder that begins in infancy. DS is dominantly caused by mutations in the SCN1A gene, which encodes the α subunit of a voltage-gated Na channel. Pre-synaptic inhibitory dysfunction is regarded as the pathophysiological mechanism, but an effective strategy for ameliorating seizures and behavioral problems is still under development. Here, we evaluated the effects of KRM-II-81, a newly developed positive allosteric modulator for α 2/3 subunit containing GABAA receptors (α2/3-GABAAR) in a mice model of DS both in vivo and at the neuronal level. Methods: We used knock-in mice carrying a heterozygous, clinically relevant SCN1A mutation (background strain: C57BL/6 J) as a model of the DS (Scn1a WT/A1783V mice), knock-in mouse strain carrying a heterozygous, clinically relevant SCN1A mutation (A1783V). Seizure threshold and locomotor activity was evaluated by using the hyperthermia-induced seizure paradigm and open filed test, respectively. Anxiety-like behavior was assessed by avoidance of the center region in locomotor activity. We estimated a sedative effect by the total distance traveled in locomotor activity and grip strength. Inhibitory post synaptic currents (IPSCs) were recorded from a hippocampal CA1 pyramidal neuron in an acutely prepared brain slice. Results: KRM-II-81 significantly increased the seizure threshold of Scn1a WT/A1783V mice in a dose-dependent manner. A low dose of KRM-II-81 specifically improved anxiety-like behavior of Scn1a WT/A1783V mice. A sedative effect was induced by relatively high dose of KRM-II-81 in Scn1a WT/A1783V mice, the dose of which was not sedative for WT mice. KRM-II-81 potentiated IPSCs by increasing its decay time kinetics. This effect was more prominent in Scn1a WT/A1783V mice. Discussion: Higher activation of α2/3-GABAAR by KRM-II-81 suggests a compensatory modification of post synaptic inhibitory function against presynaptic inhibitory dysfunction in Scn1a WT/A1783V. The increased sensitivity for KRM-II-81 may be relevant to the distinct dose-dependent effect in each paradigm of Scn1a WT/A1783V mice. Conclusion: Selective activation for α2/3-GABAAR by KRM-II-81 could be potential therapeutic strategy for treating seizures and behavioral problems in DS.
  • 問題症例のMEG 構造的焦点てんかんを呈した乳児例に対する後頭葉切除と側頭葉切除(Occipital lobe dissection and temporal lobectomy for an infantile case with structural focal epilepsy.)
    平松 泰好; 中島 翠; 江川 潔; 江夏 怜; 三國 信啓; 鳴神 雅史; 植田 佑樹; 中久保 佐千子; 木村 修平; 後藤 健; 白石 秀明
    臨床神経生理学, 50, 5, 344, 344, (一社)日本臨床神経生理学会, 2022年10月
    英語
  • Late-onset obstructive hydrocephalus associated with occipital encephalocele with large skull defect successfully treated by endoscopic third ventriculostomy
    Yuki Munekata; Taku Sugiyama; Yuki Ueda; Makoto Mizushima; Hiroaki Motegi; Miki Fujimura
    Child's Nervous System, Springer Science and Business Media LLC, 2022年07月29日
    研究論文(学術雑誌)
  • 深層ニューラルネットワークを用いた長時間ビデオ脳波モニタリングビデオデータ中の患者発作検出の試み
    江口 克紀; 矢口 裕章; 中島 翠; 植田 佑樹; 江川 潔; 白石 秀明; 矢部 一郎
    てんかん研究, 40, 1, 86, 86, (一社)日本てんかん学会, 2022年06月
    日本語
  • エトスクシミドによる薬剤誘発性ループスが疑われた全身性エリテマトーデスの女児例
    佐藤 智信; 平松 泰好; 瀬越 尚人; 渡邊 康太; 白石 春生; 丸尾 優爾; 佐藤 紀夫; 菅沼 隆; 三河 誠; 植田 佑樹; 佐々木 聡
    小児科, 63, 6, 685, 691, 金原出版(株), 2022年06月
    日本語
  • Adrenal function during long‐term ACTH therapy for patients with developmental and epileptic encephalopathy
    Yuki Ueda; Shuta Fujishige; Takeru Goto; Shuhei Kimura; Noriko Namatame; Masashi Narugami; Sachiko Nakakubo; Midori Nakajima; Kiyoshi Egawa; Naoya Kaneko; Kanako Nakayama; Nozomi Hishimura; Takeshi Yamaguchi; Akie Nakamura; Hideaki Shiraishi
    Epilepsia Open, 7, 1, 194, 200, Wiley, 2021年12月14日, [査読有り], [筆頭著者, 責任著者], [国際誌]
    英語, 研究論文(学術雑誌), Some patients with developmental and epileptic encephalopathy (DEE) respond to adrenocorticotropic hormone (ACTH) therapy but relapse soon after. While long-term ACTH therapy (LT-ACTH) has been attempted for these patients, no previous studies have carefully assessed adrenal function during LT-ACTH. We evaluated the effectiveness of LT-ACTH, as well as adverse effects (AE), including their adrenal function in three DEE patients. Patients underwent a corticotropin-releasing hormone (CRH) stimulation test during LT-ACTH, and those with peak serum cortisol below 15 μg/dL were considered to be at high risk of adrenal insufficiency (AI). Two of three responded, and their life-threatening seizures with postgeneralized electroencephalogram (EEG) suppression decreased. Although no individuals had serious AE, CRH stimulation test revealed relatively weak responses, without reaching normal cortisol peak level (18 μg/dL). Hydrocortisone replacement during stress was prepared in a case with lower cortisol peak than our cutoff level. LT-ACTH could be a promising treatment option for cases of DEE that relapse soon after effective ACTH treatment. The longer duration and larger cumulative dosage in LT-ACTH than in conventional ACTH could increase the relative risk of AI. Careful evaluation with pediatric endocrinologists, including hormonal stimulation tests, might be useful for continuing this treatment safely.
  • Notable therapeutic response in a patient with systemic juvenile xanthogranuloma with KIF5B‐ALK fusion
    Minako Sugiyama; Shinsuke Hirabayashi; Yukitomo Ishi; Junko Kikuchi; Ayako Ishikura; Hiroaki Motegi; Yuki Ueda; Saori Sawai; Kazuya Hara; Yukayo Terashita; Yuko Cho; Emi Takakuwa; Shohei Honda; Shigeru Yamaguchi; Ichiro Kinoshita; Atsushi Manabe
    Pediatric Blood & Cancer, 68, 11, e29227, Wiley, 2021年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Selective Eating in Autism Spectrum Disorder Leading to Kwashiorkor and Brain Edema
    Yuji Maruo; Kiyoshi Egawa; Hidefumi Tonoki; Satoshi Terae; Yuki Ueda; Hideaki Shiraishi
    Pediatric Neurology, 116, 55, 56, Elsevier BV, 2021年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • A case report of Leigh syndrome diagnosed by endomyocardial biopsy
    Yuji Maruo; Yuki Ueda; Kei Murayama; Atsuhito Takeda
    European Heart Journal - Case Reports, 5, 2, ytaa582, Oxford University Press (OUP), 2021年02月04日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Abstract

    Background
    Leigh syndrome is a neurodegenerative disorder caused by mitochondrial dysfunction with both phenotypic and genetic heterogeneity. Mitochondrial impairments are usually demonstrated by skeletal muscle biopsy. We report a case of Leigh syndrome diagnosed by endomyocardial biopsy (EMB), not by skeletal muscle biopsy.




    Case summary
    At aged 7 months, the patient had delayed motor development. He developed metabolic acidosis triggered by an infection with elevated lactate and pyruvate values in serum and cerebrospinal fluid when he was 1 year old. T2-weighted imaging on magnetic resonance imaging of the brain revealed bilateral hyperintensity in midbrain and dorsal pons. Biopsied skeletal muscle did not show evidence of mitochondrial disease. Left ventricular hypertrophy, bilateral putamen hyperintensity in T2-weighted imaging and a lactate peak in the right basal ganglia in single voxel spectroscopy, and a convulsive seizure appeared at the age of 12, 15, and 16, respectively. When he was 17 years old, biopsied myocardium showed cytoplasmic vacuolization and a marked proliferation of mitochondria within myofibrils pathologically. Respiratory chain enzyme activity of the biopsied myocardium showed decreased activity of complex I. Genetic testing revealed an m.14453 A>G mutation on the MT-ND6 gene. He was finally diagnosed with Leigh syndrome. Administration of oral 5-aminolevulinic acid reduced the frequency of seizures.




    Discussion
    EMB led to the diagnosis of Leigh syndrome. Efforts to find and conduct the biopsy of affected organs are important to diagnose mitochondrial disease. EMB is a useful diagnostic method when there is a difficulty in diagnosing mitochondrial disease by skeletal muscle biopsy.


  • A case of severe autosomal dominant spinal muscular atrophy with lower extremity predominance caused by a de novo BICD2 mutation
    Yuki Ueda; Takashi Suganuma; Yoko Narumi-Kishimoto; Tadashi Kaname; Tomonobu Sato
    Brain and Development, 43, 1, 135, 139, Elsevier BV, 2021年01月, [査読有り], [筆頭著者, 責任著者]
    英語, 研究論文(学術雑誌)
  • Diagnostic dilemma in a case of obstructive sleep apnoea syndrome with reversible pulmonary hypertension and right heart failure: A case report
    Haruki Shiraishi; Ayako Chida-Nagai; Kota Taniguchi; Jiro Abe; Gaku Izumi; Hirokuni Yamazawa; Yuki Ueda; Osamu Sasaki; Kosei Miyakoshi; Atsuhito Takeda
    International Journal of Pediatric Otorhinolaryngology, 138, 110378, 110378, Elsevier BV, 2020年11月
    英語, 研究論文(学術雑誌)
  • Advanced dynamic statistical parametric mapping with MEG in localizing epileptogenicity of the bottom of sulcus dysplasia
    Midori Nakajima; Simeon Wong; Elysa Widjaja; Shiro Baba; Tohru Okanishi; Lynne Takada; Yosuke Sato; Hiroki Iwata; Maya Sogabe; Hikaru Morooka; Robyn Whitney; Yuki Ueda; Tomoshiro Ito; Kazuyori Yagyu; Ayako Ochi; O. Carter Snead; James T. Rutka; James M. Drake; Sam Doesburg; Fumiya Takeuchi; Hideaki Shiraishi; Hiroshi Otsubo
    Clinical Neurophysiology, 129, 6, 1182, 1191, Elsevier Ireland Ltd, 2018年06月01日, [査読有り]
    英語, 研究論文(学術雑誌)
  • Independent occurrence of de novo HSPD1 and HIP1 variants in brothers with different neurological disorders - leukodystrophy and autism.
    Yamamoto T; Yamamoto-Shimojima K; Ueda Y; Imai K; Takahashi Y; Imagawa E; Miyake N; Matsumoto N
    Human genome variation, 5, 18, 18, 2018年, [査読有り], [国際誌]
    英語, Consecutive occurrence of de novo variants in the same family is an extremely rare phenomenon. Two siblings, a younger brother with hypomyelinating leukodystrophy and an elder brother with severe intellectual disability and autistic features, had independent de novo variants of HSPD1 c.139T > G (p.Leu47Val) and HIP1 c.1393G > A (p.Glu465Lys), respectively. These novel variants were predicted to be pathogenic. Both patients also had a known MECP2 variant, c.499C > T (p.Arg167Trp).
  • Molecular genetic analysis of 30 families with Joubert syndrome
    T. Suzuki; N. Miyake; Y. Tsurusaki; N. Okamoto; A. Alkindy; A. Inaba; M. Sato; S. Ito; K. Muramatsu; S. Kimura; D. Ieda; S. Saitoh; M. Hiyane; H. Suzumura; K. Yagyu; H. Shiraishi; M. Nakajima; N. Fueki; Y. Habata; Y. Ueda; Y. Komatsu; K. Yan; K. Shimoda; Y. Shitara; S. Mizuno; K. Ichinomiya; K. Sameshima; Y. Tsuyusaki; K. Kurosawa; Y. Sakai; K. Haginoya; Y. Kobayashi; C. Yoshizawa; M. Hisano; M. Nakashima; H. Saitsu; S. Takeda; N. Matsumoto
    Clinical Genetics, 90, 6, 526, 535, Wiley, 2016年12月, [査読有り]
    研究論文(学術雑誌)
  • Loss-of-function mutations of STXBP1 in patients with epileptic encephalopathy
    Toshiyuki Yamamoto; Keiko Shimojima; Tamami Yano; Yuki Ueda; Rumiko Takayama; Hiroko Ikeda; Katsumi Imai
    BRAIN & DEVELOPMENT, 38, 3, 280, 284, 2016年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Three patients manifesting early infantile epileptic spasms associated with 2q24.3 microduplications
    Shinsaku Yoshitomi; Yukitoshi Takahashi; Mamiko Ishizuka; Tokito Yamaguchi; Akito Watanabe; Hirosato Nasu; Yuki Ueda; Hideyuki Ohtani; Hiroko Ikeda; Katsumi Imai; Hideo Shigematsu; Yushi Inoue; Yoshihiro Tanahashi; Kaori Aiba; Hodaka Ohta; Shino Shimada; Toshiyuki Yamamoto
    BRAIN & DEVELOPMENT, 37, 9, 874, 879, 2015年10月, [査読有り]
    英語, 研究論文(学術雑誌)
  • The presence of short and sharp MEG spikes implies focal cortical dysplasia
    Yuki Ueda; Kiyoshi Egawa; Tomoshiro Ito; Fumiya Takeuchi; Midori Nakajima; Kosuke Otsuka; Naoko Asahina; Kayoko Takahashi; Shingo Nakane; Shinobu Kohsaka; Hideaki Shiraishi
    EPILEPSY RESEARCH, 114, 141, 146, 2015年08月, [査読有り], [筆頭著者]
    英語, 研究論文(学術雑誌)
  • Individualized Phenytoin Therapy for Japanese Pediatric Patients With Epilepsy Based on CYP2C9 and CYP2C19 Genotypes
    Yoshiaki Yamamoto; Yukitoshi Takahashi; Katsumi Imai; Kou Miyakawa; Hiroko Ikeda; Yuki Ueda; Tokito Yamaguchi; Hirosato Nasu; Hideyuki Ohtani; Hideo Shigematsu; Yoshiyuki Kagawa; Yushi Inoue
    THERAPEUTIC DRUG MONITORING, 37, 2, 229, 235, 2015年04月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Advantageous information provided by magnetoencephalography for patients with neocortical epilepsy
    Tomoshiro Ito; Hiroshi Otsubo; Hideaki Shiraishi; Kazuyori Yagyu; Yumi Takahashi; Yuki Ueda; Fumiya Takeuchi; Kayoko Takahashi; Shingo Nakane; Shinobu Kohsaka; Shinji Saitoh
    BRAIN & DEVELOPMENT, 37, 2, 237, 242, 2015年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • An analysis of epileptic negative myoclonus by magnetoencephalography
    Masaki Yoshimura; Shouwen Zhang; Yuki Ueda; Kazumi Matsuda; Katsumi Imai; Yukitoshi Takahashi; Yushi Inoue
    EPILEPSY RESEARCH, 110, 139, 145, 2015年02月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Childhood-onset anti-MuSK antibody positive myasthenia gravis demonstrates a distinct clinical course.
    Takahashi Y; Sugiyama M; Ueda Y; Itoh T; Yagyu K; Shiraishi H; Ukeba-Terashita Y; Nakanishi M; Nagashima T; Imai T; Motomura M; Saitoh S
    Brain & development, 34, 9, 784, 786, 9, 2012年10月, [査読有り]
  • 中大脳動脈領域に孔脳症を有する症候性局在関連てんかんは手術適応となる
    植田 佑樹; 中島 翠; 大塚 耕右; 柳生 一自; 朝比奈 直子; 香坂 忍; 白石 秀明; 須藤 章; 中山 東城; 福與 なおみ; 植松 貢; 岩崎 真樹; 中里 信和; 臼井 直敬; 馬場 好一
    てんかん研究, 29, 2, 347, 347, (一社)日本てんかん学会, 2011年09月
    日本語
  • 中大脳動脈領域に孔脳症を有する症候性局在関連てんかんは手術適応となる
    植田 佑樹; 中島 翠; 大塚 耕右; 柳生 一自; 朝比奈 直子; 白石 秀明; 香坂 忍; 中山 東城; 福與 なおみ; 植松 貢; 須藤 章; 斉藤 伸治
    脳と発達, 43, Suppl., S227, S227, (一社)日本小児神経学会, 2011年05月
    日本語
  • Six patients with Kawasaki disease showing retropharyngeal low-density areas on computed tomography
    Yuki Ueda; Yoshinori Saita; Tohru Matsuzawa; Tetsuji Wada; Naoki Kanai; Ichiro Kobayashi
    Pediatrics International, 52, 4, e187, e189, Wiley, 2010年08月, [査読有り], [筆頭著者]
    研究論文(学術雑誌)
  • A longer polyalanine expansion mutation in the ARX gene causes early infantile epileptic encephalopathy with suppression-burst pattern (Ohtahara syndrome)
    Mitsuhiro Kato; Shinji Saitoh; Atsushi Kamei; Hideaki Shiraishi; Yuki Ueda; Manami Akasaka; Jun Tohyama; Noriyuki Akasaka; Kiyoshi Hayasaka
    AMERICAN JOURNAL OF HUMAN GENETICS, 81, 2, 361, 366, 2007年08月, [査読有り]
    英語, 研究論文(学術雑誌)
■ その他活動・業績
  • てんかん性脳症をきたしたSCN 2A変異の2例
    山口 解冬; 植田 佑樹; 今井 克美; 大谷 英之; 池田 浩子; 重松 秀夫; 高橋 幸利; 井上 有史; 武下 草生子; 加藤 光広; 中島 光子; 才津 浩智; 松本 直通, てんかん研究, 33, 2, 549, 549, 2015年09月
    (一社)日本てんかん学会, 日本語
  • 14番染色体p11.2q32.3に切断点を有する環状染色体例のてんかん発作型の検討
    吉冨 晋作; 山口 解冬; 渡辺 陽和; 束本 和紀; 那須 裕郷; 植田 佑樹; 大谷 英之; 池田 浩子; 重松 秀夫; 今井 克美; 高橋 幸利; 井上 有史; 深沢 達也, 脳と発達, 46, Suppl., S263, S263, 2014年05月
    (一社)日本小児神経学会, 日本語
  • Rasmussen症候群のステロイドパルス療法の検討
    渡辺 陽和; 高橋 幸利; 束本 和紀; 吉冨 晋作; 山口 解冬; 植田 佑樹; 那須 裕郷; 大谷 英之; 池田 浩子; 今井 克美; 重松 秀夫; 井上 有史, 脳と発達, 46, Suppl., S298, S298, 2014年05月
    (一社)日本小児神経学会, 日本語
  • 環状20番染色体てんかん症候群の小児例でみられた発作症状の臨床脳波学的検討
    池田 浩子; 今井 克美; 池田 仁; 植田 佑樹; 大谷 英之; 重松 秀夫; 束本 和紀; 那須 裕郷; 山口 解冬; 吉冨 晋作; 渡邉 陽和; 高橋 幸利; 井上 有史; 池上 真理子, 脳と発達, 46, Suppl., S354, S354, 2014年05月
    (一社)日本小児神経学会, 日本語
  • Rufinamideが長期に奏功しているLennox-Gastaut症候群の3小児例
    束本 和紀; 高橋 幸利; 高山 留美子; 山本 吉章; 吉冨 晋作; 渡辺 陽和; 山口 解冬; 植田 佑樹; 那須 裕郷; 大谷 英之; 池田 浩子; 今井 克美; 重松 秀夫; 井上 有史, 脳と発達, 46, Suppl., S401, S401, 2014年05月
    (一社)日本小児神経学会, 日本語
  • Dravet症候群におけるStiripentol血中濃度と有効性等との関連の検討
    那須 裕郷; 高橋 幸利; 高橋 良平; 山本 吉章; 吉冨 晋作; 渡辺 陽和; 植田 佑樹; 山口 解冬; 大谷 英之; 池田 浩子; 今井 克美; 重松 秀夫; 井上 有史, てんかん研究, 31, 2, 337, 337, 2013年09月
    (一社)日本てんかん学会, 日本語
  • LEVが有効であった限局性皮質形成異常、結節性硬化症の3例
    山口 解冬; 福山 哲広; 大谷 英之; 渡辺 陽和; 吉冨 晋作; 那須 裕郷; 植田 佑樹; 池田 浩子; 今井 克美; 重松 秀夫; 高橋 幸利; 井上 有史, てんかん研究, 31, 2, 445, 445, 2013年09月
    (一社)日本てんかん学会, 日本語
  • 新生児期にてんかんを発症し、2q24.3領域に重複が確認された2例
    吉冨 晋作; 高橋 幸利; 保立 麻美子; 山口 解冬; 植田 佑樹; 那須 裕郷; 大谷 英之; 池田 浩子; 今井 克美; 重松 秀夫; 井上 有史; 島田 姿野; 山本 俊至; 棚橋 義浩; 相場 佳織, てんかん研究, 31, 2, 471, 471, 2013年09月
    (一社)日本てんかん学会, 日本語
  • 薬物治療が有効であった片側巨脳症の検討
    高山 留美子; 今井 克美; 山口 解冬; 保立 麻美子; 植田 佑樹; 那須 裕郷; 大谷 英之; 池田 浩子; 重松 秀夫; 高橋 幸利; 井上 有史, 脳と発達, 45, Suppl., S238, S238, 2013年05月
    (一社)日本小児神経学会, 日本語
  • Dravet症候群における最終重積発作
    山口 解冬; 高橋 幸利; 保立 麻美子; 植田 佑樹; 那須 裕郷; 高山 留美子; 大谷 英之; 池田 浩子; 今井 克美; 重松 秀夫; 井上 有史, 脳と発達, 45, Suppl., S242, S242, 2013年05月
    (一社)日本小児神経学会, 日本語
  • Dravet症候群19例におけるStiripentol長期投与効果
    那須 裕郷; 高橋 幸利; 植田 佑樹; 保立 麻美子; 山口 解冬; 高山 留美子; 大谷 英之; 池田 浩子; 重松 秀夫; 今井 克美; 井上 有史, 脳と発達, 45, Suppl., S242, S242, 2013年05月
    (一社)日本小児神経学会, 日本語
  • STXBP1関連てんかん脳症のてんかんおよび神経学的所見の経時的変化
    植田 佑樹; 今井 克美; 保立 麻美子; 山口 解冬; 那須 裕郷; 高山 留美子; 大谷 英之; 池田 浩子; 重松 秀夫; 高橋 幸利; 井上 有史; 下島 圭子; 山本 俊至, 脳と発達, 45, Suppl., S350, S350, 2013年05月
    (一社)日本小児神経学会, 日本語
  • グルタミン酸受容体自己抗体 (特集 Antibody Update)
    高橋 幸利; 保立 麻美子; 植田 佑樹, Brain and nerve : 神経研究の進歩, 65, 4, 345, 353, 2013年04月
    医学書院, 日本語
  • PCDH 19-related epilepsyにおける発作症状の検討
    池田 浩子; 今井 克美; 池田 仁; 植田 佑樹; 大谷 英之; 重松 秀夫; 高山 留美子; 那須 裕郷; 保立 麻美子; 山口 解冬; 高橋 幸利; 井上 有史, てんかん研究, 30, 2, 415, 415, 2012年09月
    (一社)日本てんかん学会, 日本語
  • 脳炎脳症後てんかんの慢性期におけるステロイドパルス治療での脳波変化
    山口 解冬; 高橋 幸利; 保立 麻美子; 植田 佑樹; 那須 裕郷; 高山 留美子; 大谷 英之; 池田 浩子; 今井 克美; 重松 秀夫; 井上 有史, てんかん研究, 30, 2, 376, 376, 2012年09月
    (一社)日本てんかん学会, 日本語
  • Prader-Willi症候群を疑われる児の鑑別診断
    斉藤 伸治; 細木 華奈; 植田 佑樹; 伊藤 智城; 高橋 有美; 柳生 一自; 白石 秀明; 太田 亨; 新川 詔夫, 脳と発達, 42, 6, 474, 474, 2010年11月
    (一社)日本小児神経学会, 日本語
■ 主な担当授業
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院